* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Infectious Complications of Human T Cell Leukemia/Lymphoma
Neglected tropical diseases wikipedia , lookup
Common cold wikipedia , lookup
Urinary tract infection wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Tuberculosis wikipedia , lookup
Globalization and disease wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
West Nile fever wikipedia , lookup
Sociality and disease transmission wikipedia , lookup
Sarcocystis wikipedia , lookup
Henipavirus wikipedia , lookup
Marburg virus disease wikipedia , lookup
Schistosomiasis wikipedia , lookup
Hepatitis C wikipedia , lookup
Neonatal infection wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
138 Infectious Complications of Human T Cell Leukemia/Lymphoma Virus Type I Infection Bryan J. Marsh From the Infectious Disease Section, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire Infection with human T cell leukemiallymphoma virus type I (HTLV-I) has been etiologically associated with two diseases: adult T cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. Increasing evidence suggests that HTLV-I infection may be associated with immunosuppression and, as a consequence, affect the risk and expression of several other infectious diseases, of which the best studied are strongyloidiasis, tuberculosis, and leprosy. In strongyloidiasis, coinfection with HTLV-I appears to result in a higher rate of chronic carriage, an increased parasite load, and a risk of more severeinfection. In tuberculosis, a decreasein delayed-typehypersensitivity to Mycobacterium tuberculosis has beenestablished, but whether this decreaseis clinicallysignificant has yet to be determined. In leprosy, an increased risk of disease is suggested, but the published studies are all too poorly controlled to draw definite conclusions. The spectrum of immune dysregulation produced by viral infections is wide, spanning the transient and relatively benign leukopenia associated with many acute viral infections to the progressive CD4 lymphocytopenia and profound immunodeficiency associated with chronic infection with HIV. Despite our rapidly growing understanding of many aspects of these infections, the immunologic consequences of chronic infection by viruses other than HIV remain poorly understood. Viruses of obvious concern in this regard include human T cell leukemia! lymphoma virus types I and II (HTLV-I and HTLV-II). Both viruses produce lifelong latent infection, and both infect T lymphocytes (HTLV-I, primarily CD4+ cells; HTLV-II, primarily CD8+ cells). HTLV-I is now known to be etiologically associated with at least two diseases, and there is extensive and impressive literature on the in vitro immune modulation produced by the virus. HTLV-II on the other hand remains an orphan virus, without any confirmed disease association. This review focuses on the clinical and epidemiologic studies that pertain to a possible immune perturbation produced by latent infection with HTLV-I and its consequent effects on the risks of coinfection with other infectious agents. Much has been learned about the virology, epidemiology, and natural history of HTLV-I since its discovery in the late 1970s [1, 2]. These subjects have been reviewed recently, and only relevant aspects will be detailed here [3]. HTLV-I and HTLV-II are the only members of the Oncovirnae subfamily of the family Retroviridae known to infect humans. HTLV-I primarily infects CD4+ cells, with subsequent integration of the viral genome into the genome of the host's CD4+ cells. Received 11 October 1995; revised 21 February 1996. Reprints or correspondence: Dr. Bryan J. Marsh, Infectious Disease Section, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756. Clinical Infectious Diseases 1996;23:138-45 © 1996 by The University of Chicago. All rights reserved. 1058--4838/96/2301-0019$02.00 While HTLV-I infection is in this latent state, which can last indefinitely, it is able to avoid immunologic surveillance despite the fact that the viral genome can be found polyclonally integrated in up to 15% of circulating T lymphocytes [4-6]. The only proven modes of transmission of HTLV-I are sexual, parenteral (via transfusion and needle sharing), and vertical (congenitally and via breast-feeding), but the possibility of environmental and vector-borne transmission is still debated [7-11]. HTLV-I is found worldwide, but the prevalence of HTLVI infection varies widely both over large geographic areas and within areas of endemicity. The two areas with the highest prevalence rates are the Caribbean basin (4%-9% [8]) and the islands of southwestern Japan (37% [12]). One study of global seroprevalence estimates that between 11 and 20 million people are currently infected with HTLV-I [13]. In the United States, the combined prevalence rates of HTLV-I and HTLV-II infections in >600,000 blood donors was 0.05%; about 40% of these donors were infected with HTLV-I, and the remainder were infected with HTLV-II [14]. The major risk factors for infection in the blood donor studies in the United States were origin from an area of endemicity and sexual intercourse with a partner from such an area [15]. Intravenous drug use has also been shown to be a significant risk for infection with HTLV-I in the United States [16,17]. Diagnosis of infection with HTLV-I is usually serological and is complicated by significant cross-reactivity with HTLVII [18]. Specific peptide tests and PCR now allow for accurate distinction between the two viruses [19], but in clinical studies performed before 1990, this distinction was not possible. Unless otherwise noted, the studies discussed below were all performed in areas with endemic HTLV-I but not HTLV-II. Natural History Infection with HTLV-I is persistent and lifelong. In a small percentage of infected individuals, one of the noninfectious ern 1996;23 (July) Infectious Complications of HTLV-I Infection clinical sequelae subsequently develops, but most of these individuals are thought to remain asymptomatic. There are only two diseases, adult T cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), definitively associated with HTLV-I infection. ATL ATL is the most common major sequela of infection with HTLV-I, and in areas of endemicity, it occurs in ~4% of HTLV-I-infected individuals [20]. The median age of onset of ATL in one study was 56 years [21], suggesting a period of latent infection as long as several decades. This suggestion is supported by a model for the risk of ATL that was based on a combination of cross-sectional data and a case-control study from Jamaica [20], and this model has led to the assumption that most, if not all, cases of ATL develop in individuals infected with HTLV-I since birth [22]. ATL can present in one of several forms (which may be stages in the natural history of ATL). Although there is significant geographic variation in the contribution of these forms to the initial presentation, the most common presentation is acute leukemia. The most benign detectable form of ATL is an asymptomatic preleukemic phase usually diagnosed incidentally when examination of a peripheral blood smear reveals abnormal lymphocytes with characteristic lobulated nuclei. About one-half of patients with this preleukemic phase have spontaneous resolution, but the conditions ofthe other one-half eventually progress to a symptomatic stage of disease [23]. Smoldering ATL is the most benign symptomatic form of disease and is characterized by cutaneous but no visceral lesions, a normal peripheral blood leukocyte count, and a few circulating leukemic cells. The development of chronic ATL is marked by visceral involvement and is evidenced by lymphadenopathy, hepatosplenomegaly, and peripheral blood leukocytosis. Both of the relatively benign or early forms of symptomatic ATL can progress to acute ATL. Acute ATL is a fulminant disease; the median life expectancy of individuals with acute ATL is 11 months. Patients with acute ATL have cutaneous and visceral involvement, peripheral blood leukocytosis, elevated levels of lactate dehydrogenase and bilirubin, and often hypercalcemia. As recently reviewed by Rhew et al. [24], ATL is associated with severe immunosuppression as evidenced by the susceptibility of these patients to various opportunistic infections, including Pneumocystis carinii pneumonia, cryptococcal meningitis, candidal esophagitis, and disseminated cytomegalovirus infection. Occasional longterm survival has been described, but the disease is usually unresponsive to conventional chemotherapy. Recent reports of immunotherapeutic trials allow for a degree of optimism [25]. HAM/TSP The second of the two syndromes associated with chronic infection with HTLV-I is HAM/TSP, also known as HTLV-I 139 myelopathy. This syndrome afflicts < 1% of individuals from areas of endemicity who are infected with HTLV-I [26]. Patients are largely adults, although somewhat younger than those who have ATL. On the basis of cases associated with blood transfusion, a median latent period of infection as short as 3.3 years has been described [27], thus suggesting that most cases occur in individuals who acquired HTLV-I infection as adults rather than vertically. The syndrome is one of progressive spastic paraparesis, predominantly of the lower extremities, and is associated with hyperreflexia, sensory disturbances, and urinary incontinence [28]. Cognitive function and cranial nerves are not affected. The pathology is demyelination, primarily in the spinal cord. Other Putative Disease Correlations There have been many other noninfectious syndromes associated with latent HTLV-I infection, but none of these syndromes have been definitively linked to HTLV-I. Among the more likely putative correlates are uveitis [29, 30], polymyositis [31], lymphocytic interstitial pneumonia [32], inflammatory arthritis [33-35], and mycosis fungoides [36-38]. Asymptomatic Infection Most ('"'-'95%) individuals chronically infected with HTLV1have been thought to remain entirely asymptomatic. However, a growing body of literature suggests that some or many of these infected individuals may have a mild but clinically significant form of chronic immunosuppression. Clinical Evidence for Immunosuppression in Chronic HTL V-I Infection The immunosuppression associated with ATL is well documented [39]. There is also now a considerable volume of in vitro and clinical evidence suggesting a significant perturbation of the immune function in individuals with asymptomatic HTLV-I infection (table 1). Evidence includes an increased risk of acute and chronic infection by several pathogens, an increased rate of reactivation tuberculosis, case reports of opportunistic infections, and depressed cell-mediated immunity as demonstrated by skin testing for delayed-type hypersensitivity (DTH). The most consistent and convincing evidence involves the interaction between HTLV-I infection and three infections-strongyloidiasis, tuberculosis, and leprosy (table 2). Strongyloidiasis Studies on the association between Strongyloides stercoralis infection and HTLV-I infection have been conducted in both Japan [40-43, 64, 65] and Jamaica [44-46, 55]. These studies used serological and microbiological methods, which are not directly comparable, to define S. stercoralis infection. Sero- Marsh 140 Table 1. Clinical evidence that chronic HTLV-I infection is immunosuppressive. Effect of chronic HTLV-I infection Increased prevalence of Strongyloidiasis Leprosy Chronic skin sores Increased severity of Strongyloidiasis Norwegian scabies Novel infection Infective dermatitis Opportunistic infections Cryptococcosis Pneumocystis carinii pneumonia Kaposi's sarcoma Depressed cell-mediated immunity Anergy to PPD NOTE. [Reference(s)] [40-46] [47-49] [50] [44,51-55] [56] [57] [58] [59] [60] [61-63] HTLV-I = human T cell leukemia/lymphoma virus type I. prevalence studies determine the number of individuals who were ever infected, and stool culture studies determine the number of individuals who are currently infected. If HTLV-I has an effect on the host's ability to clear infection with Strongyloides rather than on the risk of acquiring infection, one would expect equal seroprevalencesof antibodies to Strongyloides in HTLV-I-positive and HTLV-I-negative groups but a higher prevalence of Strongyloides in stool from HTLV-I-positive patients. In addition, the titers of antibody to Strongyloides in patients coinfected with HTLV-I may steadily decline [51]. If this is a common phenomenon in individuals infected with HTLV-I, then a falsely low serological estimate of S. stercoralis infection in HTLV-I-positive subjects might result. Therefore,studies based on stool culture for S. stercoralis provide a better method for detecting HTLV-I-induced immunosuppression than do studies based on seroprevalence of S. stercoralis infection. In Japan, several stool culture studies documented that the risk of active infection with S. stercoralis is significantly higher in subjects who are HTLV-I-positive than in subjects who are HTLV-I-negative [40-43]. The studies were primarily from areas where HTLV-I is endemic and examined results from both HTLV-I serologies for subjects for whom stool cultures were positive for Strongyloides and stool cultures for subjects known to be HTLV-I-positive. These studies usually found a relative risk of strongyloidiasis of ......,3-4. The details of case and control selection were often not presented, but the samples were large enough and the prevalence rates of HTLV-I infection were high enough that a significant association between HTLV-I infection and stool carriage of Strongyloides seems likely in Japan. Two stool culture studies from Japan were unable to demonstrate an association between HTLV-I infection and S. stercoralis carriage [64, 65]; however, both studies have significant limitations. Both studies used a highly sensitive technique for em 1996;23 (July) stool culture that does not distinguish minimal carriage from more significant disease. In addition, one study [64] failed to perform simultaneous HTLV-I serologies for cases and controls, failed to consider confounding variables that might affect the epidemiology of either of these infections in two very different locations, and compared populations by means of data collected in two different studies. In Jamaica, studies based on stool culture for S. stercoralis also showed an association with HTLV-I [44, 45]. Terry et al. [44] found that 12 (44%) of27 patients for whom stool cultures were positive for strongyloidiasis were HTLV-I-positive, while oof 13 controls (minor or no gastrointestinal disease) for whom stool cultures were negative were HTLV-I-positive. Likewise, in a survey of 67 persons, Robinson et al. [45] found that 67% of patients for whom stool cultures were positive were HTLVI-positive, while only 15% of patients for whom stool cultures were negative were HTLV-I-positive (P = .01). A study in Jamaica that used seroprevalence as the definition of infection with S. stercoralis failed to show an association with HTLV-I infection [55]. This study of94 HTLV-I-positive and 106 HTLV-I-negative healthy food handlers found no difference in Strongyloides seropositivity between the two groups (29% vs. 25%, respectively; P = .36). The discrepancy between serological and stool culture studies was addressed in an outpatient study from Jamaica [46]. Serological studies for HTLV-I and Strongyloides were performed on nine patients with symptomatic strongyloidiasis for whom stools were positive for Strongyloides and on 198 asymptomatic subjects who were from areas geographically clustered around the areas where the initial cases were from. Larvae were found in the stools of eight (4%) of the asymptomatic subjects (combined prevalence of stool carriage, 17 [8.2%] of 207). The seroprevalence of strongyloides infection in the combined sample of patients was 62 (30%) of 207. HTLV-I positivity was found in 14 (22.6%) of 62 of the Strongyloidesseropositive subjects and nine (6.2%) of 145 of Strongyloidesseronegative subjects, while HTLV-I positivity was found in 10 (58.8%) of 17 subjects for whom stools were positive for Strongyloides and 13 (6.8%) of 190 subjects for whom stools were negative for Strongyloides. The increased HTLV-I positivity in the Strongyloides-seropositive subjects was attributable to the high rate of HTLV-I positivity in the symptomatic subjects for whom stools were positive; therefore, this increased positivity reflects the bias introduced by the inclusion of nine nonrandomly selected symptomatic subjects into the study population and does not represent a real association between HTLV-I infection and seroprevalence of strongyloides infection. However, the increased HTLV-I positivity in the subjects for whom stools were positive for Strongyloides could not be attributed solely to the inclusion of the nine symptomatic subjects and thus appears to represent a real association. Therefore, prior infection with Strongyloides is not more common in HILV-I-positive subjects, but active infection is. cm 1996;23 Infectious Complications of HTLV-I Infection (July) 141 Table 2. Evidence for an immunomodulatory effect ofHTLV-I infection on infection withand disease produced by three human pathogens. Immunomodulatory effect [reference(s)] Pathogen, manifestation Strongyloides stercoralis Serological studies show no relationship between HTLV-I infection and risk of infection with S. stercoralis [46, 55]. Most stool culture studies show a positive association between HTLV-I and parasite load and HTLV-I and rate ofchronic carriage of S. stercoralis [4046]. Two negative stool culture studies have significant design limitations [64, 65]. Disease may be more severe as suggested by several case reports [44, 51-54] and by the observation that reports of S. stercoralis hyperinfection are often from areas where HTLV-I is endemic [66]; however. there are no controlled studies orcase series. Infection Disease Mycobacterium tuberculosis No pertinent studies have been reported. The only study that has examined the effect ofHTLV-I infection on the risk of tuberculosis failed to show a positive association but was inconclusive (inadequate controls and only five subjects infected with HTLV-I) [67]. No studies address a possible effect ofcoinfection with HTLV-Ion the severity of tuberculosis. Several studies demonstrate a significant suppression ofdelayed-type hypersensitivity to PPD in subjects with HTLV-I infection [61-63]. Infection Disease Other Mycobacterium leprae No pertinent studies have been reported. Three studies demonstrate a positive association between infection with HTLV-I and the risk of leprosy [47-49]. The one negative study was inconclusive (only three HTLV-I-infected subjects) [68]. No studies address an effect of HTLV-I infection on the severity ofleprosy. Infection Disease NOTE. HTLV-I = human T cell leukemia/lymphoma virus type I. The clinical sequelae of coinfection with HTLV-I and S. stercoralis have not been well defined. The Japanese prevalence studies all lack sufficient clinical data for determining if strongyloidiasis is clinically distinct in HTLV-I-positive individuals. Case reports, however, suggested that coinfection with these two pathogens might lead to more severe strongyloidiasis [44,51-54]; these reports described HTLV-I-positive patients with symptomatic, often severe, strongyloidiasis refractory to usually effective therapy. In addition, Neva [66] noted that cases of hyperinfection with S. stercoralis are often described in patients from areas in which HTLV-I is endemic. A partial explanation for the increased severity of strongyloidiasis in individuals coinfected with HTLV-I is offered by Robinson et al. [45]. These authors noted markedly reduced titers of total serum IgE in coinfected patients; Robinson et al. suggested that, if the serum IgE levels correlated with intestinal mucosal levels, this might' 'permit increased rates of autoinfection of the parasite and result in correspondingly greater worm loads and patient morbidity." If an association between HTLV-I infection and strongyloidiasis exists, an important question is whether the HTLV-Iinfected population is uniformly at risk or whether the risk may be present just in specific subgroups. This issue was addressed by Nakada et al. [69] who examined 36 coinfected patients in Japan who were receiving therapy for various condi- tions. Fourteen (39%) of these subjects had monoclonal integration ofHTLV-I proviral DNA in peripheral blood lymphocytes, 7 (19%) had polyclonal integration, and 15 (42%) had undetectable proviral DNA. Monoclonal integration of viral DNA is indicative of clonal expansion and is a necessary, although probably not sufficient, step in the pathogenesis of ATL. There was a trend, although not statistically significant, toward moresevere clinical strongyloidiasis in the group with monoclonal integration of HTLV-I proviral DNA. Since ATL develops in <4% of individuals infected with HTLV-I [20], the study by Nakada et al. [69] suggests that a disproportionate number of patients with strongyloidiasis may have ATL. In addition, several of the case reports of severe strongyloidiasis also mention eventual progression to ATL. This progression implies either that S. stercoralis influences the development of ATL or that S. stercoralis is a marker of significant immune dysfunction in some patients infected with HTLV-I. Thus, one subset of individuals at risk of strongyloidiasis may be patients with an early form of preleukemic ATL. However, this association could explain only a small proportion of the patients with coinfection. In summary, infection with HTLV-I does not appear to influence the risk of primary infection with S. stercoralis. However, it seems likely that coinfection with HTLV-I does alter the host's immune response to S. stercoralis, resulting in a 142 Marsh higher rate of chronic carriage, an increased parasite load, and a risk of more severe infection. Tuberculosis The host's immune response to Mycobacterium tuberculosis is critically dependent on T cell function. Because HTLV-I causes chronic T cell infection, several studies have investigated the effect of HTLV-I infection on both infection and disease due to M tuberculosis [61-63, 67]. Two lines of investigation have addressed the immunologic effects of HTLV-I infection on the risk of tuberculosis. The more extensive evidence concerns the effect of HTLV-I infection on DTH to PPD. Three studies from Japan demonstrated a significant suppression ofDTH to PPD [61-63]. In the largest and most recent study, PPD skin tests were performed on a cohort of 528 subjects in a study of the natural history of HTLV-I infection in Japan (the Miyazaki Cohort) [62]. The subjects included 378 HTLV-I-negative subjects, 125 HTLVI-positive subjects without abnormal peripheral blood lymphocytes, and 25 HTLV-I-positive subjects with abnormal peripheral blood lymphocytes. The three groups were purportedly demographically similar, although details, including those on BCG vaccination, were not presented. PPD reactions were evaluated on the basis of both erythema and induration. The relative risk for a reduced PPD reaction was 2.6 among seropositive subjects, which was a significant difference that persisted after correction for the older age of the seropositive group. No difference in risk was detected in seropositive subgroups on the basis of the presence of abnormal lymphocytes, antibody to tax, or detectable proviral DNA. These results supported those from two earlier studies [61, 63]. The authors concluded that there is a clinically detectable deficit in DTH to PPD in patients with asymptomatic HTLVI infection and that "sub-clinical immune suppression in HTLV-I carriers is a process associated with carriers per se, and not with increased viral replication or load." A reduced response to PPD skin tests reflects an alteration in immunologic function that could be associated with a reduction in the immune surveillance necessary to prevent reactivation of latent tuberculosis, but the extent of this effect has not been adequately investigated. Only one study has directly addressed this issue, but it was conducted in an area with a low prevalence of infection with HTLV-I. Kaplan et al. [67] selected 197 consecutive patients in Senegal, West Africa, who were admitted to the hospital with the diagnosis of pulmonary tuberculosis; they matched these subjects by age, gender, and ethnic group to 197 controls from a large study of HIV infection at another hospital. All cases and controls were tested for antibodies to HTLV-I and HIV. Three (1.5%) of the cases with tuberculosis were coinfected with HTLV-I vs. two (1.02%) ofthe controls. In contrast, 11 (5.6%) of the cases but only three (1.5%) of the controls were coinfected with HIV (OR, 3.4). The authors concluded em 1996;23 (July) that there was an association between HIV infection and active tuberculosis but not between HTLV-I infection and active tuberculosis. The conclusions of Kaplan et al. [67] need to be viewed with skepticism for several reasons. First, controls were selected from a population potentially very distinct from the study population. Second, because of the low prevalence of HTLVI infection, the study had power to detect only an odds ratio for tuberculosis in patients infected with HTLV-I (4.2) that was higher than that (3.4) for tuberculosis in patients infected with HIV. Finally, an odds ratio of 3.4 for tuberculosis in patients infected with HIV is significantly lower than odds ratios reported in other studies [70- 76] and again raises concern about the comparability of the cases and controls. Thus, an effect of HTLV-Ion DTH to M. tuberculosis has been established, but whether this effect translates into an increased risk of reactivation tuberculosis has yet to be demonstrated. A case-control or a longitudinal study of a population among whom the prevalence of both HTLV-I infection and tuberculosis is high is needed to settle this question. Leprosy Leprosy is another mycobacterial disease that has been described with increased frequency in subjects coinfected with HTLV-I. The first case report of coinfection with HTLV-I and Mycobacterium leprae appeared in 1990 [77], and three subsequent studies have examined the association between these two infections [47-49]. In the first of two reports, Verdier et al. [47] performed a serological survey of 3,177 subjects from the Ivory Coast, West Africa. The prevalence rate of HTLV-I infection was 3.5% but varied widely among subsets of the study population, from 16.7% among a group of socioeconomically deprived prostitutes to <2% among pregnant women from two of the surveyed areas. An association with leprosy was suggested by the fact that one of the higher rates of HTLV-I infection was detected among a population of persons with leprosy who were recruited from a single village. In an attempt to better define the association between HTLVI infection and leprosy, Verdier et al. [48] subsequently performed serological studies on 1,493 patients with clinical leprosy and 1,866 controls (matched by gender and age, when possible, and by region for three countries) from four West African countries. The seroprevalence ofHTLV-I infection was too low in two of the four countries (0 of 168 cases in Yemen and 3 of 508 cases in Senegal) to determine a possible relationship with leprosy. In Congo and the Ivory Coast, however, there were enough cases to document an increased risk of HTLV-I infection in leprosy cases compared with controls (5.6% vs. 1.9%, respectively, in Congo and 5.7% vs. 1.5%, respectively, in the Ivory Coast). In a smaller study from Zaire, Kashala et al. [49] performed serologies for HTLV-I, HTLV-I1, and HIV type 1 on 57 inpatients with leprosy, 39 asymptomatic close contacts of these ern 1996; 23 (July) Infectious Complications of HTLV-I Infection patients (among whom the rate of asymptomatic leprosy was thought to be high), and 500 pregnant women from a prenatal clinic 64 km from the leprosarium. Prevalence rates of HTLV1 infection were 8.8% among patients with leprosy, 12.8% among contacts, and among pregnant women. The contrasting seroprevalence rates of HIV type 1 infection were 3.5%, 0, and 3.6%, respectively. The authors concluded that HTLV-I infection but not HIV infection may be a risk factor for leprosy. The conclusions of this study should not be considered definitive since the controls were not comparable with the cases. The one contradictory study is a seroprevalence study of 250 Ethiopian patients with leprosy and 248 controls (mostly dermatology patients without leprosy) [68]. This study failed to show an association between HTLV-1infection and leprosy, but there were only three HTLV-I-infected subjects in the entire study. In summary, two inadequately controlled studies showed an association between HTLV-I infection and leprosy [47, 49]. This association suggests that individuals coinfected with HTLV-I and M leprae may have clinical leprosy more readily than those infected with M. leprae alone. An association between leprosy and HTLV-I infection might seem surprising given the absence of an association between leprosy and HIV infection, but because of the long latent period in leprosy, it is possible that most patients with HIV infection die before symptomatic leprosy develops. ° 143 Coinfection with HIV Both HIV and HTLV-I infect CD4 + lymphocytes; therefore, a possible interaction between these viruses in coinfected individuals needs to be considered [83,84]. The concern is justified by several reports that have documented a more rapid progression of clinical immunodeficiency in coinfected subjects than in those infected with HIV alone [85-87], although only one of these studies distinguished HTLV-I from HTLV-II [85]. Schechter et al. [85] performed a retrospective case-control study of 27 subjects coinfected with HIV and HTLV-I and 99 controls infected with HIV only. The authors found higher CD4 + lymphocyte counts but significantly more advanced clinical disease in the coinfected subjects. Conclusions An epidemiologic and etiologic association between HTLVI infection and both ATL and HAM/TSP is clear; however, these are the only documented sequelae, and they develop in <5% of infected individuals. On the other hand, a sizable body of literature now suggests that HTLV-I infection is associated with an increased risk of three infectious diseases: strongyloidiasis, tuberculosis, and leprosy. Thus, chronic HTLV-I infection may be immunosuppressive. HTLV-I infection does not produce the profound immunodeficiency state associated with HIV infection, but even a mild form of immunodeficiency could have significant medical and public health implications. Other Infections Case reports and small uncontrolled series have described occasional opportunistic infections and an increased frequency of various infections in HTLV-l-positive subjects [50, 56-60, 78]. These infections include a chronic relapsing form of eczema associated with infection with Staphylococcus aureus and ,B-hemolytic streptococci [57], Norwegian scabies and chronic skin sores [50, 56], pulmonary cryptococcosis [58], and P. carinii pneumonia [59]. Kaposi's sarcoma has been described in one patient [60], and protracted chancres due to Treponema pal/idum have been described in a rabbit model of HTLV-I infection [78]. Of these infections, only the eczematous disease has been shown to be more than coincidental. An unusual infective dermatitis was first described in Jamaican children in 1966 [79], and the clinical features of this infection were defined in 1967 [80]. Infective dermatitis is an acute illness with severe exudation from which S. aureus and ,B-hemolytic streptococci can routinely be cultured. An association with HTLV-I infection was demonstrated in 1990 by LaGrenade et al. [57] who found that all of 14 Jamaican children with infective dermatitis were seropositive for HTLV-I, while none of 11 children with atopic dermatitis were seropositive. The natural history of infective dermatitis is not well defined; ATL may develop in a disproportionate number of subjects, but most appear to remain hematologically normal [57, 81, 82]. Acknowledgments The author thanks C. Fordham von Reyn, M.D., and Farley R. Cleghorn, M.D., for their very helpful critical evaluations of this manuscript. References 1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481-92. 2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-9. 3. Hollsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993;328:1173-82. 4. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990;64:5682-7. 5. Greenberg SJ, Jacobson S, Waldmann TA, McFarlin DE. Molecular analysis of HTLV-I proviral integration and T cell receptor arrangement indicates that T cells in tropical spastic paraparesis are polyclonal. J Infect Dis 1989; 159:741-4. 6. Hollsberg P, Wucherpfennig KW, Ausubel LJ, Calvo V, Bierer BE, Hafler DA. Characterization of HTLV-I in vivo infected T cell clones: IL-2 independent growth of nontransformed T cells. J Immunol 1992; 148: 3256-63. 144 Marsh 7. Blattner WA. Epidemiology of HTL V-I and associated diseases. In: Blattner WA, ed. Human retrovirology: HTLV. New York: Raven Press, 1990:251-65. 8. Maloney EM, Murphy EL, Figueroa JP, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica: II. Geographic and ecologic determinants. Am J Epidemiol 1991; 133:1125-34. 9. Miller GJ, Lewis LL, Colman SM, et al. Clustering of human T lymphotropic virus type I seropositivity in Montserrat, West Indies: evidence for an environmental factor in transmission of the virus. J Infect Dis 1994; 170:44-50. 10. Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986; 154:851-7. II. Kinoshita K, Amagasaki T, Hino S, et al. Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 1987; 78:674-80. 12. Maeda Y, Furukawa M, Takehara Y, et al. Prevalence of possible adult T-cell leukemia virus-carriers among volunteer blood donors in Japan: a nation-wide study. Int J Cancer 1984;33:717-20. 13. de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9:381-6. 14. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 1991; 337: 1435-9. 15. Eble BE, Busch MP, Guiltinan AM, Khayam-Bashi H, Murphy EL. Determination of human T lymphotropic virus type by polymerase chain reaction and correlation with risk factors in northern California blood donors. J Infect Dis 1993; 167:954-7. 16. Cantor KP, Weiss SH, Goedert JJ, Battjes RJ. HTLV-I111 seroprevalence and HlV/HTLV coinfection among U.S. intravenous drug users. J Acquir Immune Defic Syndr 1991;4:460-7. 17. Khabbaz RF, Onorato 1M, Cannon RO, et al. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992;326:375-80. 18. Cossen C, Hagens S, Fukuchi R, Forghani B, Gallo D, Ascher M. Comparison of six commercial human T-cell lymphotropic virus type I (HTLVI) enzyme immunoassay kits for detection of antibody to HTLV-I and II. J Clin Microbiol 1992;30:724-5. 19. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplementary serologic testing for human T-Iymphotropic virus types I and II in US blood donors. Blood 1994;83:1143-8. 20. Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989;43:250-3. 21. Yamaguchi K, Kiyokawa T, Futami G, Takatsuki K. Pathogenesis of adult T-cell leukemia from clinical pathological features. In: Blattner WA, ed. Human retrovirology: HTLV. New York: Raven Press, 1990: 163-71. 22. Hino S. ATL development after adult infection of HTLV-I? [letter]. Jpn J Cancer Res 1989;80:1016. 23. Kinoshita K, Amagasaki T, Ikeda S, et al. Preleukemic state of adult T cell leukemia: abnormal T lymphocytosis induced by human adult T cell leukemia-lymphoma virus. Blood 1985;66:120-7. 24. Rhew DC, Gaultier CR, Daar ES, Zakowski PC, Said J. Infections in patients with chronic adult T-cell leukemia/lymphoma: case report and review. Clin Infect Dis 1995;21:1014-6. 25. Waldmann TA. Human T-celllymphotropic virus type I-associated adult T-cell leukemia. The Joseph Goldberger clinical investigator lecture. JAMA 1995;273:735-7. 26. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLVI-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-101. 27. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-Iassociated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990;28:50-6. em 1996;23 (July) 28. Shibasaki H, Endo C, Kuroda Y, Kakigi R, ada K, Komine S. Clinical picture of HTLV-I associated myelopathy. J Neurol Sci 1988;87: 15-24. 29. Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992;83:236-9. 30. Mochizuki M, Tajima K, Watanabe T, Yamaguchi K. Human T lymphotropic virus type I uveitis. Br J Ophthalmoll994;78:149-54. 31. Morgan as, Rodgers-Johnson P, Mora C, Char G. HTLV-I and polymyositis in Jamaica. Lancet 1989; 2: 1184-7. 32. Setoguchi Y, Takahashi S, Nukiwa T, Kira S. Detection of human T-cell lyrnphotropic virus type l-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis 1991; 144:1361-5. 33. Kitajima I, Yamamoto K, Sato K, et al. Detection of human T cell lymphotropic virus type I proviral DNA and its gene expression in synovial cells in chronic inflammatory arthropathy. J Clin Invest 1991; 88: 1315-22. 34. Ijichi S, Matsuda T, Maruyama I. Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann Rheum Dis 1990;49:718-21. 35. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I [letter]. Lancet 1989; 1:441. 36. Manca N, Piacentini E, Gelmi M, et al. Persistence of human T cell lymphotropic virus type I (HTLV-I) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides. J Exp Med 1994; 180:1973-8. 37. Pancake BA, Zucker-Franklin D, Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virusassociated disease: a study of 50 patients. J Clin Invest 1995;95: 547-54. 38. Hall WW. Human T cell lymphotropic virus type I and cutaneous T cell leukemia/lymphoma. J Exp Med 1994; 180:1581-5. 39. Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirusassociated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309:257 -64. 40. Hanada S, Uematsu T, Iwahashi M, et al. The prevalence of human Tcell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan. Cancer 1989;64:1290-5. 41. Nakada K, Kohakura M, Komoda H, Hinuma Y. High incidence of HTLV antibody in carriers of Strongyloides stercoralis [letter]. Lancet 1984; 1:633. 42. Sato Y, Shiroma Y. Concurrent infections with Strongyloides and T-cell leukemia virus and their possible effect on immune responses of host. Clin Immunol ImmunopathoI1989;52:214-24. 43. Sato Y, Toma H, Takara M, Kiyuna S, Shiroma Y. Seroepidemiological studies on the concomitance of strongyloidiasis with T-cell leukemia viral infection in Okinawa, Japan. Japanese Journal of Parasitology 1990; 39(4):376-83. 44. Terry S, Blattner W, Neva F, et al. Coincidental HTLV-I infection influences outcome of treatment of strongyloidiasis. West Indian Med J 1989; 38(suppl 1):36. 45. Robinson RD, Lindo JF, Neva FA, et al. Interaction between HTLV-I and Strongyloides stercora lis infection resulting in lowered IgE titres in Jamaica. West Indian Med J 1990;39(suppl):35-6. 46. Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercora lis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169:692-6. 47. Verdier M, Denis F, Sangare A, et al. Prevalence of antibody to human T cell leukemia virus type I (HTLV-I) in populations of Ivory Coast, West Africa. J Infect Dis 1989; 160:363-70. 48. Verdier M, Denis F, Sangare A, et al. Antibodies to human T lymphotropic virus type I in patients with leprosy in tropical areas [letter]. J Infect Dis 1990; 161:1309-10. 49. Kashala 0, Marlink R, Ilunga M, et al. Infection with human immunodeficiency virus type I (HlV-I) and human T cell lymphotropic viruses ern 1996;23 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. (July) Infectious Complications of HTL V-I Infection among leprosy patients and contacts: correlation between HIV-I crossreactivity and antibodies to lipoarabinomannan. J Infect Dis 1994; 169: 296-304. Mollison LC. HTLV-I and clinical disease correlates in central Australian aborigines [letter]. Med J Aust 1994; 160:238. Newton RC, Limpuangthip P, Greenberg S, Gam A, Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med 1992; 92:202 - 8. Dixon AC, Yanagihara ET, Kwock DW, Nakamura JM. Strongyloidiasis associated with human T-cell Iymphotropic virus type I infection in a nonendemic area. West J Med 1989; 151:410-3. Patey 0, Gessain A, Breuil J, et al. Seven years of recurrent severe strongyloidiasis in an HTLV-I-infected man who developed adult 'l-cell Ieukaemia. AIDS 1992;6:575-9. Sato Y, Shiroma Y, Kiyuna S, Toma H, Kobayashi 1. Reduced efficacy of chemotherapy might accumulate concurrent HTLV-I infection among strongyloidiasis patients in Okinawa, Japan. Trans R Soc Trop Med Hyg 1994; 88:59. Neva FA, Murphy EL, Gam A, Hanchard B, Figueroa JP, Blattner WA. Antibodies to Strongyloides stercoralis in healthy Jamaican carriers of HTLV-I [letter]. N Engl J Med 1989;320:252-3. Mollison LC, Lo STH, Marning G. HTLV-I and scabies in Australian aborigines [letter]. Lancet 1993; 341: 1281- 2. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTL V-I infection. Lancet 1990;336:1345-7. Kohno S, Koga H, Kaku M, et al. Prevalence of HTLV-I antibody in pulmonary cryptococcosis. Tohoku J Exp Med 1992; 167:13-8. Ikeda S, Momita S, Kinoshita K-i, et al. Clinical course of human TIymphotropic virus type I carriers with molecularly detectable monoclonal proliferation of T lymphocytes: defining a low- and high-risk population. Blood 1993;82:2017-24. Zucker-Franklin D, Huang YQ, Grusky GE, Friedman-Kien AE. Kaposi's sarcoma in a human immunodeficiency virus-negative patient with asymptomatic human T Iymphotropic virus type I infection [letter]. J Infect Dis 1993; 167:987-9. Murai K, Tachibana N, Shioiri S, et al. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr 1990; 3: 1006- 9. Welles SL, Tachibana N, Okayama A, et al. Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status. Int J Cancer 1994; 56:337 -40. Tachibana N, Okayama A, Ishizaki J, et al. Suppression of tuberculin skin reaction in healthy HTLV -I carriers from Japan. Int J Cancer 1988; 42: 829-31. Arakaki T, Kohakura M, Asato R, Ikeshiro T, Nakamura S, Iwanaga M. Epidemiological aspects of Strongyloides stercoralis infection in Okinawa, Japan. J Trop Med Hyg 1992;95:210-3. Arakaki T, Asato R, Ikeshiro T, Sakiyama K, Iwanaga M. Is the prevalence of HTLV-I infection higher in Strongyloides carriers than in non-carriers? Trop Med ParasitoI1992;43:199-200. Neva FA. Letter to the editor: a reply to Strongyloides hyperinfection in patients coinfected with HTLV-I and S. stercoralis. Am J Med 1993; 94:448-9. Kaplan JE, Camara T, Hanne A, Green D, Khabbaz R, LeGuenno B. Low prevalence of human T-Iymphotropic virus type I among patients with 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 145 tuberculosis in Senegal [letter]. J Acquir Immune Defic Syndr 1994; 7: 418-20. Tekle-Haimanot R, Frommel D, Tadesse T, Verdier M, Abebe M, Denis F. A survey ofHTLV-I and HIVs in Ethiopian leprosy patients [letter]. AIDS 1991;5:108-10. Nakada K, Yamaguchi K, Furugen S, et al. Monoclonal integration of HTLV-I proviral DNA in patients with strongyloidiasis. Int J Cancer 1987;40:145-8. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545 - 50. Colebunders RL, Ryder RW, Nzilambi N, et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis 1989; 139: 1082-5. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-l-infected patients in Kenya. Lancet 1993;342:332-7. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194-8. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268:504-9. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis 1991; 143:501--4. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439-44. Harle J-R, Disdier P, Kaplanski G, et al. Lepromatous leprosy and seropositivity for HTLV-1. Am J Med 1990;89:535. Tseng C-TK, Sell S. Protracted Treponema pallidum-induced cutaneous chancres in rabbits infected with human T-cell leukemia virus type 1. AIDS Res Hum Retroviruses 1991; 7:323·- 31. Sweet RD. A pattern of eczema in Jamaica. Br J Dermatol 1966; 78: 93-100. Walshe MM. Infective dermatitis in Jamaican children. Br J Dermatol 1967; 79:229--36. Hanchard B. LaGrenade L, Carberry C, et al. Childhood infective dermatitis evolving into adult T-cell leukaemia after 17 years [letter]. Lancet 1991; 338: 1593-4. Tsukasaki K, Yamada Y, Ikeda S, Tomonaga M. Infective dermatitis among patients with ATL in Japan [letter]. Int J Cancer 1994;57:293. Kanner SB, Parks ES, Scott GB, Parks WP. Simultaneous infections with human T cell leukemia virus type I and the human immunodeficiency virus. J Infect Dis 1987; 155:617-25. Robert-Guroff M, Weiss SH, Giron JA, et al. Prevalence of antibodies to HTLV-I, -II, and -Ill in intravenous drug abusers from an AIDS endemic region. JAM A 1986;255:3133-7. Schechter M, Harrison LH, Halsey NA. et al. Coinfection with human Tcell Iymphotropic virus type I and HIV in Brazil: impact on markers of HIV disease progression. JAM A 1994; 271:353· 7. Page 18, Lai S, Chitwood DD, Klimas NG, Smith PC, Fletcher MA. HTLV-I/II seropositivity and death from AIDS among HIV-I seropositive intravenous drug users. Lancet 1990;335:1439-41. Lee HH, Weiss SH, Brown LS, et al. Patterns of HIV-l and HTLV-I/II in intravenous drug abusers from the middle Atlantic and central regions of the USA. J Infect Dis 1990; 162:347 52.